Cargando…

TRIM5α is a SUMO substrate

BACKGROUND: The TRIM5α restriction factor interferes with retroviral infections by inhibiting an early step of viral replication. TRIM5α activity was recently proposed to be regulated by the SUMO machinery and one SUMO consensus conjugation site as well as three putative SUMO interacting motifs (SIM...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutrieux, Jacques, Portilho, Débora M, Arhel, Nathalie J, Hazan, Uriel, Nisole, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376147/
https://www.ncbi.nlm.nih.gov/pubmed/25880753
http://dx.doi.org/10.1186/s12977-015-0155-7
_version_ 1782363691185864704
author Dutrieux, Jacques
Portilho, Débora M
Arhel, Nathalie J
Hazan, Uriel
Nisole, Sébastien
author_facet Dutrieux, Jacques
Portilho, Débora M
Arhel, Nathalie J
Hazan, Uriel
Nisole, Sébastien
author_sort Dutrieux, Jacques
collection PubMed
description BACKGROUND: The TRIM5α restriction factor interferes with retroviral infections by inhibiting an early step of viral replication. TRIM5α activity was recently proposed to be regulated by the SUMO machinery and one SUMO consensus conjugation site as well as three putative SUMO interacting motifs (SIMs) were identified within TRIM5α sequence. Whereas mutation of the SIM sequences was found to abolish TRIM5α antiviral activity, mutation of the consensus SUMO conjugation site did not affect its restriction capacity, although this putative site has never been shown to be actually a SUMO substrate. FINDINGS: Here we further demonstrate that TRIM5α relies on the SUMO machinery to promote restriction, since SUMO1 overexpression enhances TRIM5α-mediated retroviral inhibition whereas knockdown of SUMO1 or E2 SUMO conjugating enzyme Ubc9 prevents restriction. Furthermore, we show for the first time that TRIM5α is SUMOylated both in vitro and in cellulo and that Lysine 10 is the main SUMOylation site. Mutation of the consensus SUMO conjugation motif in position 10 abrogated SUMOylation at this position, but did not disrupt TRIM5α antiviral activity. CONCLUSIONS: Altogether, our results confirm that the SUMO machinery is involved in TRIM5α-mediated retroviral restriction, and demonstrate that TRIM5α is a SUMO 1 and SUMO 2 substrate. The inability to abrogate TRIM5α antiviral activity by mutating its main SUMO conjugation motif supports the notion that non-covalent interaction with SUMO or SUMOylated proteins rather than TRIM5α direct SUMOylation is required.
format Online
Article
Text
id pubmed-4376147
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43761472015-03-28 TRIM5α is a SUMO substrate Dutrieux, Jacques Portilho, Débora M Arhel, Nathalie J Hazan, Uriel Nisole, Sébastien Retrovirology Short Report BACKGROUND: The TRIM5α restriction factor interferes with retroviral infections by inhibiting an early step of viral replication. TRIM5α activity was recently proposed to be regulated by the SUMO machinery and one SUMO consensus conjugation site as well as three putative SUMO interacting motifs (SIMs) were identified within TRIM5α sequence. Whereas mutation of the SIM sequences was found to abolish TRIM5α antiviral activity, mutation of the consensus SUMO conjugation site did not affect its restriction capacity, although this putative site has never been shown to be actually a SUMO substrate. FINDINGS: Here we further demonstrate that TRIM5α relies on the SUMO machinery to promote restriction, since SUMO1 overexpression enhances TRIM5α-mediated retroviral inhibition whereas knockdown of SUMO1 or E2 SUMO conjugating enzyme Ubc9 prevents restriction. Furthermore, we show for the first time that TRIM5α is SUMOylated both in vitro and in cellulo and that Lysine 10 is the main SUMOylation site. Mutation of the consensus SUMO conjugation motif in position 10 abrogated SUMOylation at this position, but did not disrupt TRIM5α antiviral activity. CONCLUSIONS: Altogether, our results confirm that the SUMO machinery is involved in TRIM5α-mediated retroviral restriction, and demonstrate that TRIM5α is a SUMO 1 and SUMO 2 substrate. The inability to abrogate TRIM5α antiviral activity by mutating its main SUMO conjugation motif supports the notion that non-covalent interaction with SUMO or SUMOylated proteins rather than TRIM5α direct SUMOylation is required. BioMed Central 2015-03-24 /pmc/articles/PMC4376147/ /pubmed/25880753 http://dx.doi.org/10.1186/s12977-015-0155-7 Text en © Dutrieux et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Short Report
Dutrieux, Jacques
Portilho, Débora M
Arhel, Nathalie J
Hazan, Uriel
Nisole, Sébastien
TRIM5α is a SUMO substrate
title TRIM5α is a SUMO substrate
title_full TRIM5α is a SUMO substrate
title_fullStr TRIM5α is a SUMO substrate
title_full_unstemmed TRIM5α is a SUMO substrate
title_short TRIM5α is a SUMO substrate
title_sort trim5α is a sumo substrate
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376147/
https://www.ncbi.nlm.nih.gov/pubmed/25880753
http://dx.doi.org/10.1186/s12977-015-0155-7
work_keys_str_mv AT dutrieuxjacques trim5aisasumosubstrate
AT portilhodeboram trim5aisasumosubstrate
AT arhelnathaliej trim5aisasumosubstrate
AT hazanuriel trim5aisasumosubstrate
AT nisolesebastien trim5aisasumosubstrate